It’s an unfortunate fact that the morbidity rate due to fatty liver, especially nonalcoholic fatty liver (NAFL), is close to 25% in the Asia-Pacific region, and the number rises to nearly 30% in Europe and North America. NAFL can progress to nonalcoholic steatohepatitis (NASH), and is considered a hepatic manifestation of metabolic syndrome, which is related to obesity, hypertension, and oxidant stresses. No medication exists today to eradicate fatty liver, which makes monitoring liver parameters an especially significant gauge of personal health.
Adding to known proof that Glutathione serves to support the reduction of free radicals, clinical research undertaken by KOHJIN and Yokohama City University, a member of the Japan Study Group of Nonalcoholic Fatty Liver, proved – for the first time ever – that OPITAC™ Glutathione improved major clinical parameters of liver health (AST, ALT), lipid metabolism (FFA, VO2/VCO2), inflammation (Ferritin), and image-view observation (Fibroscan) significantly, after 16 weeks of OPITAC™ intake. (PCT Patent Pub. No. WO2016140237)
Please click here for more information.